Hologic Adds COVID-19 Test to Global Access Initiative in Resource-Limited Countries

By Sam Brusco, Associate Editor | 01.06.22

Expanded access to critical diagnostic testing with the Aptima SARS-CoV-2 assay.

Hologic has added its Aptima SARS-CoV-2 assay to its Global Access Initiative (GAI), a program that aims to boost access to diagnostic testing in countries with limited resources.
 
The company launched the GAI at 2018’s International AIDS Conference. Qualified products included molecular assays for human immunodeficiency virus-1 (HIV-1), hepatitis B and C (HBV and HCV) and human papillomavirus (HPV), and the ThinPrep Pap test for cervical cancer screening.
 
“Hologic remains committed to building diagnostic capacity and equitable health systems through affordable and accessible technical innovation,” Joao Malagueira, Hologic’s VP EMEA commercial told the press. “We have a responsibility to bridge the diagnostic gap to sustainably control current and future disease outbreaks globally, and the expansion of the GAI to include our Aptima SARS-CoV-2 assay empowers countries to respond to the pandemic and control new waves of COVID-19.”
 
Partnerships with the World Health Organization, UNICEF, the Global Fund to Fight AIDS, Tuberculosis, and Malaria, and the U.S. President’s Emergency Plan for AIDS Relief assisted countries in quickly receiving SARS-CoV-2 tests. Hologic’s Aptima SARS-CoV-2 assay is also available via the WHO Diagnostics Consortium.
 
To date, Hologic has provided over 700,000 COVID-19 tests to resource-limited countries. The company also routinely supplied tests for other viral infections.